Breast最新文献

{"title":"Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03","authors":"Olivier Trédan ,&nbsp;Delphine Loirat ,&nbsp;Sylvie Chabaud ,&nbsp;Philippe Toussaint ,&nbsp;Thierry Petit ,&nbsp;Frédéric Viret ,&nbsp;Christelle Levy ,&nbsp;Aurélien Robert ,&nbsp;Julien Grenier ,&nbsp;Laura Mansi ,&nbsp;Jean-Philippe Spano ,&nbsp;Anne Patsouris ,&nbsp;Olfa Derbel ,&nbsp;Christelle Jouannaud ,&nbsp;Jean Marc Ferrero ,&nbsp;Jean Sébastien Frenel ,&nbsp;Yann Molin ,&nbsp;Louis Doublet ,&nbsp;Pierre-Etienne Heudel ,&nbsp;Jean-Yves Pierga ,&nbsp;Thomas Bachelot","doi":"10.1016/j.breast.2025.104648","DOIUrl":"10.1016/j.breast.2025.104648","url":null,"abstract":"<div><h3>Background</h3><div>Triple negative breast cancer (TNBC) patients with residual disease after neoadjuvant chemotherapy (NAC) face high risk of recurrence. BREASTIMMUNE-03 trial evaluates the efficacy of nivolumab and ipilimumab combination compared to capecitabine as adjuvant treatment.</div></div><div><h3>Methods</h3><div>This multicentre, randomized open-label phase II trial included TNBC patients with Residual Cancer Burden (RCB) of class II-III after NAC and surgery, and allocated them to randomization (1:1) to receive nivolumab plus ipilimumab or capecitabine for 24 weeks. Randomization was stratified by center, ECOG performance status (PS) 0 or 1, and RCB Class. Primary endpoint was disease free survival (DFS), assessed in the intent-to-treat population. Safety analysis according to NCI-CTCAE V5.0 included all patients who received at least one dose of study drug.</div></div><div><h3>Results</h3><div>From July 2019 to October 2021, 95 patients were randomized to the nivolumab plus ipilimumab arm (NIVO + IPI n = 45), or to the capecitabine arm (CT n = 50). With a median follow-up of 34.3 (IQR 33–36) months, 39 events (relapse or death) were reported: 17 (38 %) for NIVO + IPI; 22 (44 %) for CT (HR 0.84, 95 %CI 0.45–1.59; log-rank test p-value 0.5938). 17 (38 %) patients in the NIVO + IPI arm prematurely discontinued treatment due to treatment-related adverse events (AEs), <em>versus</em> 7 (14 %) in the CT arm.</div></div><div><h3>Conclusion</h3><div>A 6-month post-operative nivolumab plus ipilimumab treatment did not significantly improve DFS compared to capecitabine in TNBC patients with RCB II-III and resulted in increased immune-mediated AEs. Despite premature trial termination, our results do not support nivolumab plus ipilimumab adjuvant treatment in this setting.</div></div><div><h3>Trial registration</h3><div>NCT03818685.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104648"},"PeriodicalIF":7.9,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subcutaneous pertuzumab-trastuzumab: Efficiency, safety, and the biosimilar horizon.","authors":"Asim Armagan Aydin, Erkan Kayikcioglu","doi":"10.1016/j.breast.2025.104651","DOIUrl":"https://doi.org/10.1016/j.breast.2025.104651","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":" ","pages":"104651"},"PeriodicalIF":7.9,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145582103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Climate change impacts and sustainability integration among breast international group members\" [The Breast Volume 81 June 2025 104469].","authors":"Seamus O'Reilly, Jessica Griffiths, Lisa Fox, Catherine S Weadick, Nay My Oo, Lucy Murphy, Robert O'Leary, Theodora Goulioti, Virginie Adam, Evangelia D Razis, Barbro Lindholm, Gustavo Werutsky, David Cameron, Judith Bliss","doi":"10.1016/j.breast.2025.104653","DOIUrl":"https://doi.org/10.1016/j.breast.2025.104653","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":" ","pages":"104653"},"PeriodicalIF":7.9,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145547880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of treatment response to neoadjuvant chemotherapy on brain metastasis patterns and breast cancer prognosis","authors":"Jihwan Yoo ,&nbsp;Yoon Jin Cha ,&nbsp;Sung Gwe Ahn ,&nbsp;Joon Jeong ,&nbsp;Hun Ho Park ,&nbsp;Sung Jun Ahn ,&nbsp;Bio Joo ,&nbsp;Ji Hyun Park ,&nbsp;Jee Hung Kim ,&nbsp;Soong June Bae","doi":"10.1016/j.breast.2025.104650","DOIUrl":"10.1016/j.breast.2025.104650","url":null,"abstract":"<div><h3>Background</h3><div>Brain metastases (BM) are a major cause of mortality in breast cancer. While pathologic complete response (pCR) after neoadjuvant chemotherapy is associated with favorable survival outcomes, its impact on BM development and prognosis remains unclear.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 1,244 patients with early-stage breast cancer who underwent neoadjuvant chemotherapy followed by surgery. Clinicopathological features, BM incidence, and survival outcomes were assessed. Propensity score matching (PSM) was applied to adjust for baseline differences. Gene expression profiling was performed in BM samples from pCR and non-pCR patients.</div></div><div><h3>Results</h3><div>Of these, 437 (35.1 %) patients achieved pCR and 52 (4.2 %) developed BM. In TNBC, non-pCR patients had a significantly higher BM rate (9.2 % vs. 3.3 %, <em>P</em> = 0.026), whereas no differences were observed in other subtypes. Patients with BM who achieved pCR were more likely to present with single brain lesion (42.9 % vs. 10.5 %, <em>P</em> = 0.016), undergo craniotomy (71.4 % vs. 31.6 %, <em>P</em> = 0.010), and less frequently had extracranial metastases (28.6 % vs. 73.7 %, <em>P</em> = 0.003). Median overall survival after BM was longer in the pCR (42 vs. 4 months, <em>P</em> = 0.002), and this benefit remained significant after PSM (43 vs. 10 months, <em>P</em> = 0.033). Transcriptomic analysis identified distinct molecular profiles, with upregulation of RPL27A and CTLA4 in pCR BM and non-pCR BM.</div></div><div><h3>Conclusions</h3><div>pCR was associated with lower metastatic burden and improved survival following BM diagnosis. Molecular differences between pCR and non-pCR BM suggest distinct mechanisms of metastatic evolution, suggesting the need for tailored surveillance and preventive strategies.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104650"},"PeriodicalIF":7.9,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical appraisal of a machine learning model for predicting internal mammary lymph node metastasis in breast cancer.","authors":"Kun Fang, Suxiao Jiang, Ping Zhang","doi":"10.1016/j.breast.2025.104652","DOIUrl":"https://doi.org/10.1016/j.breast.2025.104652","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":" ","pages":"104652"},"PeriodicalIF":7.9,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145629741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Ki67 change predicts prognosis and supports response-adapted therapy in breast cancer treated with neoadjuvant chemotherapy","authors":"Ying Zhang ,&nbsp;Siyu Wu ,&nbsp;Liang Xue ,&nbsp;Yifan Xie ,&nbsp;Juping Shen ,&nbsp;Zhimin Shao ,&nbsp;Guangyu Liu","doi":"10.1016/j.breast.2025.104649","DOIUrl":"10.1016/j.breast.2025.104649","url":null,"abstract":"<div><h3>Background</h3><div>Early prediction of response to neoadjuvant chemotherapy (NACT) in breast cancer is critical for optimizing treatment strategies and improving outcomes. This study assessed the prognostic value of early Ki67 change (ΔKi67 %) via on-treatment core needle biopsy (CNB) in stratifying event-free survival (EFS) and informing potential treatment escalation.</div></div><div><h3>Methods</h3><div>In this prospective cohort study, 1388 breast cancer patients treated from 2013 to 2021 were randomly divided into training and validation sets (7:3 ratio). ΔKi67 % was calculated as the percentage change from baseline to on-treatment CNB after a median of two NACT cycles. K-means clustering determined an optimal 40 % cutoff classifying patients as poor (≤40 %) or good responders (&gt;40 %). EFS was analyzed using Kaplan-Meier estimates, multivariable Cox models, and restricted mean survival time (RMST).</div></div><div><h3>Results</h3><div>Good responders had significantly superior 5-year EFS compared to poor responders in both training (78.8 % versus 62.4 %, p &lt; 0.001) and validation (78.6 % versus 60.9 %, p = 0.001) sets. ΔKi67 % showed stronger stratification than imaging-based metrics in RMST analysis and remained an independent predictor after adjustment. Subgroup analyses suggested poor responders in the ER-negative/HER2-negative subgroup derived a 32.0 % 3-year EFS benefit from chemotherapy intensification. The 3-year survival benefit was 14.1 % in poor responders in the HER2-positive subtype with dual HER2 blockade, though these findings require further validation.</div></div><div><h3>Conclusion</h3><div>Early ΔKi67 % change using a 40 % cutoff via on-treatment CNB is a reliable prognostic predictor supporting response-adapted treatment tailoring, particularly in ER-negative/HER2-negative and HER2-positive populations.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104649"},"PeriodicalIF":7.9,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-related quality of life and fear of recurrence after early breast cancer treatment: Results from a cross-sectional survey","authors":"Paola Mosconi ,&nbsp;Secondo Folli ,&nbsp;Rosalba Miceli ,&nbsp;Serena Scrudato ,&nbsp;Massimiliano Gennaro ,&nbsp;Gabriele Tinè ,&nbsp;Maria Carmen De Santis ,&nbsp;Cristina Ferraris ,&nbsp;Gabriele Martelli ,&nbsp;Immacolata Di Carlo ,&nbsp;Ilaria Maugeri ,&nbsp;Alessio Arata ,&nbsp;Maria Grazia Carnevale ,&nbsp;Chiara Listorti ,&nbsp;Roberto Agresti ,&nbsp;Claudia Borreani ,&nbsp;Claudio Vernieri ,&nbsp;Giancarlo Pruneri ,&nbsp;Paolo Baili ,&nbsp;Valentina Appierto ,&nbsp;Giovanni Apolone","doi":"10.1016/j.breast.2025.104647","DOIUrl":"10.1016/j.breast.2025.104647","url":null,"abstract":"<div><h3>Background</h3><div>The growing population of breast cancer survivors has raised attention to the long-term effects of treatment and follow-up. This study explored how survivors experience follow-up care and its impact on quality of life, focusing on fear of cancer recurrence (FCR), work and financial burden.</div></div><div><h3>Methods</h3><div>In this monocentric observational study, survivors completed a questionnaire including validated items from GIVIO, EORTC QLQ-C30, and FCR Inventory Short-Form. Fourteen domains were assessed. Scores were scaled 0–100, with higher values indicating better outcomes, except for FCR, where higher scores indicate greater concern. Data were stratified by age, time since diagnosis, education, income. Cluster analysis uncovered patterns of survivor experience across questionnaire domains.</div></div><div><h3>Results</h3><div>Of 1565 women scheduled for follow-up over six months, 681 (43.5 %) agreed to participate and, after excluding patients not fulfilling the protocol, and questionnaires with &gt;50 % missing data, 656 entered the final analysis. Mean quality of life (73.3), physical (75.6), and social functioning (82.7) scored high, while emotional (55.6) and cognitive functioning (61.6) were lower. Satisfaction with care was mixed, with lower ratings for the national health system-level (56.8). FCR was moderate overall (38), with recurrent/intrusive thoughts in 2.9 % and 5.6 % of respondents. Lower income was significantly associated with worse outcomes across several domains, while no relevant differences were observed by age, education, or time since diagnosis. Cluster analysis revealed two distinct response profiles, clearly distinguished only by socioeconomic status.</div></div><div><h3>Conclusions</h3><div>Breast cancer survivors reported overall good levels of functioning, with lower scores in emotional and cognitive domains. Socioeconomic status was the only factor clearly associated with distinct response patterns.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104647"},"PeriodicalIF":7.9,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145569974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eligibility for bilateral prophylactic mastectomy: An expert opinion study in the Netherlands","authors":"L.P. Jansen ,&nbsp;G.M. Kramer ,&nbsp;E.G. Engelhardt ,&nbsp;C.W. van der Zee ,&nbsp;I. van de Beek ,&nbsp;M.A. Adank ,&nbsp;M.T.F.D. Vrancken Peeters ,&nbsp;M.K. Schmidt ,&nbsp;C.A. Drukker","doi":"10.1016/j.breast.2025.104645","DOIUrl":"10.1016/j.breast.2025.104645","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104645"},"PeriodicalIF":7.9,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145569972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A UK study of the experiences, information needs and attitudes to clinical research among patients living with secondary breast cancer in the UK: A prospective co-developed study","authors":"Lesley Stephen ,&nbsp;Janet Dunn ,&nbsp;Claire Balmer ,&nbsp;Nada Elbeltagi ,&nbsp;Sophie Gasson ,&nbsp;Ellen Copson ,&nbsp;Carlo Palmieri","doi":"10.1016/j.breast.2025.104644","DOIUrl":"10.1016/j.breast.2025.104644","url":null,"abstract":"<div><h3>Background</h3><div>Clinical research is key to improving the outcomes of patients with metastatic breast cancer (MBC). However, participation is low, with little data on patients’ attitudes and experiences of clinical research. This study aimed to explore the experience and attitude of patients in accessing and participating in clinical research in the UK.</div></div><div><h3>Methods</h3><div>An online survey, available between May and November 2021, was open to people living with MBC in the UK; this was complemented with by qualitative interviews.</div></div><div><h3>Findings</h3><div>768 responses were received (766 female, 2 male); median age was 51–60 years with 235 (31 %) having de novo disease. 660 (86 %) respondents were confident in their understanding of clinical research. Discussion of participation in research with an oncologist was reported by 173 (23 %) respondents. Accessing new treatments was the most common reason for study participants wanting to take part in research, 737 (96 %). Of the 107 (14 %) respondents who had taken part in clinical trials, 77 (72 %) reported a positive experience. 276 (36 %) would consider travelling to participate in research and 430 (56 %) would be more likely to travel if expenses were met. Themes emerging from the qualitative interviews include ‘lack of information’, ‘barriers to participation’ and ‘participants research priorities’.</div></div><div><h3>Interpretation</h3><div>This is the largest UK prospective study in regards to the views of MBC patients towards research. It demonstrates keenness to be involved in research, but participants face barriers as well as a lack of opportunity for participation. Key messages include importance of clinical staff in providing research information, need to develop patient accessible information, and to support travel costs. Improvements within the UK health care system are necessary to enable MBC patients to have equitable access to clinical research.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104644"},"PeriodicalIF":7.9,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145570208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Silent Spring” revisited: Implications for breast cancer care","authors":"Seamus O'Reilly ,&nbsp;Hans Wildiers ,&nbsp;Alexandra Thomas","doi":"10.1016/j.breast.2025.104643","DOIUrl":"10.1016/j.breast.2025.104643","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104643"},"PeriodicalIF":7.9,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145518956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}